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icuspid Aortic Valve Disease
eyond the Aortic Root
otential Prognostic Implications
or Ascending Aortic Dilation*
. Morteza Farasat, MD
armington, Connecticut
ith an estimated incidence of 1% to 2% in the general
opulation (1), bicuspid aortic valve (BAV) afflicts more
atients than all other congenital heart anomalies combined
2). One-third of all patients with BAV experience one of
he serious complications of BAV, including aortic stenosis,
ortic regurgitation, infective endocarditis, and aortic dis-
ection, in their lifetime (3).
See page 660
Aortic root dilation is an important, potentially lethal
omplication of BAV (4) that substantially increases the risk
f ascending aortic aneurysm, dissection, and rupture (3).
uriously, aortic valve replacement does not prevent pro-
ressive dilation of the ascending aorta (5), suggesting that
echanisms unrelated to hemodynamic factors, or to the
alve per se, contribute to the aortopathy of BAV. Aortic
oot dilation occurs in nearly one-half of all patients with
AV (6–8). However, presently there are no prognostic
actors to help identify the patients who are at an increased
isk of developing ascending aortic dilation.
Given the strong heritability of BAV (9), genetic factors
re thought to play a role in the pathogenesis of ascending
ortic dilation in patients with BAV. Such a view gains
upport from a recent prospective study by Biner et al. (7),
ho discovered aortic root dilation in one-third of the
rst-degree relatives of BAV patients who had normal
ricuspid aortic valves. Those investigators also found that
ndexes of aortic stiffness were higher in both BAV patients
nd their first-degree relatives compared with normal con-
rol subjects, irrespective of the presence of aortic root
ilation or hypertension status (7). Genetic factors, espe-
ially those that regulate extracellular matrix turnover, have
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.i
From the Division of Cardiology, Department of Medicine, University of Con-
ecticut School of Medicine, Farmington, Connecticut.een implicated as putative mechanisms for these observa-
ions. Most notable among these are the genes that regulate
he balance between various members of the matrix metal-
oproteinase (MMP) family and their tissue inhibitors
TIMPs).
Gene expression studies have documented increased ex-
ression of several MMPs, particularly MMP-2 and the
atio of MMP-2 to its tissue inhibitor, TIMP-1, in aortic
issues from BAV patients compared with subjects with a
ricuspid aortic valve with or without aortic aneurysms
10–12). There is general agreement that this differential
attern of gene expression contributes to the classic patho-
ogical finding of aortic medial degeneration (4), character-
zed by loss of collagen and elastin fragmentation in the
ortas of patients with BAV (10,11).
Another interesting observation is that deficiency of
ndothelium-derived nitric oxide, a key regulator of
ndothelium-dependent flow-mediated vasodilation, also
eems to play a role in the defective valvulogenesis of BAV.
n an experimental study, Lee et al. (13) showed that
ndothelium-derived nitric oxide synthase (eNOS) knock-
ut mice had a significantly higher likelihood of developing
AV than control mice. This is corroborated by human
tudies documenting lower eNOS gene expression in the
scending aortas of BAV patients than in ascending aortas
f control subjects with a tricuspid aortic valve (14).
The study by Tzemos et al. (15) in this issue of the
ournal provides an integrating view of the aforementioned
athophysiological factors in BAV patients. In their obser-
ational study, Tzemos et al. (15) cross-sectionally evaluated
2 men with BAV, without significant aortic stenosis, who
ere classified as having nondilated or dilated ascending
ortas. Brachial artery flow-mediated vasodilation, carotid-
emoral pulse wave velocity (PWV), circulating plasma
evels of MMP-2 and -9, as well as their respective tissue
nhibitors, TIMP-1 and -2, were measured in the 2 BAV
roups and in 16 healthy male control subjects. The
nvestigators found that plasma levels of MMP-2 were
igher in men with BAV and dilated aortas compared with
oth BAV subjects with nondilated aortas and normal
ontrol subjects. However, the plasma levels of MMP-9,
IMP-1, and TIMP-2 did not differ among the 3 study
roups. Although plasma levels of MMPs do not necessarily
irror their tissue activity (16), the feasibility and ease of
easuring plasma MMPs compared with in vivo determi-
ation of their activity in aortic tissue render plasma levels of
MPs an attractive candidate as a prognostic marker for
uture ascending aortic dilation in BAV patients.
The finding of impaired flow-mediated vasodilation, a
allmark of systemic endothelial dysfunction, in BAV pa-
ients with dilated aortas but not in those without dilated
ortas suggests that endothelial dysfunction may represent a
isk factor for the development of ascending aortic dilation.
his finding provides a preliminary rationale for investigat-
ng whether statins, which are known to have salutary effects
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scending aortic dilation.
Consistent with previous studies (7,18), Tzemos et al.
15) observed a higher PWV in BAV patients with dilated
ortas compared with those with nondilated aortas and with
ormal control subjects. However, the PWV was similar in
AV patients with nondilated aortas and normal control
ubjects. According to the Moens-Korteweg equation:
WV  Eh/D, where Eh is the aortic elastance-wall
hickness product,  is the density of blood, and D is the
essel diameter, PWV is inversely related to the square root
f the aortic diameter. Thus, for a given Eh, a larger vessel
iameter would be expected to result in a lower PWV.
owever, in the study by Tzemos et al. (15), subjects with
ilated aortas had a higher PWV than the other 2 groups,
ho had smaller aortic root diameters. This finding indi-
ates that the lowering effect of the larger aortic root
iameter on PWV in BAV patients with dilated aortas was
ounteracted by a more pronounced increase in the aortic
lastance–wall thickness product, reflecting the pathological
lterations in the aortic wall of BAV patients with dilated
ortas.
The cross-sectional design and the exclusion of women
rom the study sample are the 2 most important limitations
f the study by Tzemos et al. (15). Nonetheless, this study
ays the groundwork for the future development of a risk
tratification paradigm for predicting the development of
scending aortic dilation in patients with BAV. If the
ndings reported by Tzemos et al. (15) are corroborated in
rospective studies, documenting that they pre-date ascend-
ng aortic dilation, they may provide useful tools for risk
tratification and thus guide surveillance and clinical man-
gement of patients with BAV.
eprint requests and correspondence: Dr. S. Morteza Farasat,
niversity of Connecticut School of Medicine, Division of Car-
iology, 263 Farmington Avenue, Farmington, Connecticut
6030. E-mail: farasats@mail.nih.gov.
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